Anthrax Clinical Trial
Official title:
A Study of The Effects of Co-Administering Ciprofloxacin and BioThrax on the Pharmacokinetics of Ciprofloxacin in Healthy Adults
The purpose of this clinical trial is to determine whether there is any effect on the antibiotic, ciprofloxacin when taken before and after administration of a 3-dose series of BioThrax® (Anthrax Vaccine Adsorbed or AVA). This study will be conducted in the United States (US) in 154 healthy male and female volunteer subjects ages 18 to 45. The duration of study participation for each subject will be approximately 76 days (approximately 2.5 months)
BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. This is a randomized, open-label, Phase 2, multi-center trial to investigate the potential interactions of ciprofloxacin and BioThrax. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00114621 -
Anthrax Vaccine Clinical Trials
|
Phase 1 | |
| Recruiting |
NCT00050310 -
Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
|
||
| Completed |
NCT01453907 -
Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
|
Phase 1 | |
| Completed |
NCT01491607 -
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
|
Phase 3 | |
| Completed |
NCT03518125 -
BARDA Securing Anthrax Immunity For the Elderly
|
Phase 2 | |
| Completed |
NCT04660201 -
Anthrax AV7909 Liquid vs Lyophilized
|
Phase 1 | |
| Completed |
NCT04320485 -
Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
|
||
| Recruiting |
NCT06365073 -
A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
|
||
| Completed |
NCT03877926 -
VELOCITY: An Anthrax Vaccine Clinical Study
|
Phase 3 | |
| Completed |
NCT03498027 -
Febrile Whole Blood Specimen Collection and Testing
|
||
| Terminated |
NCT00964834 -
Ph1 Study of Valortim and Doxycycline in Humans
|
Phase 1 | |
| Completed |
NCT00063843 -
Anthrax-rPA: Safety, Tolerability, Immunogenicity
|
Phase 1 | |
| Completed |
NCT01624532 -
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
|
Phase 2 | |
| Completed |
NCT04148118 -
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
|
Phase 1 | |
| Terminated |
NCT05672875 -
Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System
|
||
| Completed |
NCT01770743 -
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
|
Phase 2 | |
| Completed |
NCT01867957 -
Efficacy and Safety of Anthrax Vaccine, GC1109
|
Phase 1 | |
| Completed |
NCT00845650 -
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
|
Phase 1/Phase 2 | |
| Completed |
NCT00031291 -
Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin
|
N/A | |
| Not yet recruiting |
NCT03569514 -
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
|